Answers are grounded in this paper and cite their sources.
Among patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, treatment with nivolumab resulted in longer overall survival than treatment with standard, single-agent therapy. (Funded by Bristol-Myers Squibb; CheckMate 141 ClinicalTrials.gov number, NCT02105636 .).
No takes yet. Share an insight, caveat, or question.
Ferris et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: